| Clinical Decision Support Tool for Vancomycin Dosing in Children (NCT04911270) | University of Maryland, Baltimore | 2022-05-09 |
| The Clinical Character，Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens. (NCT04917380) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2021-06-10 |
| Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition (NCT04847921) | University of Colorado, Denver | 2021-04-30 |
| Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) (NCT03896685) | Médecins Sans Frontières, France | 2020-04-06 |
| TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection (NCT03964493) | TenNor Therapeutics Limited | 2019-04-20 |
| Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection (NCT03747497) | MicuRx | 2018-11-15 |
| Controlled Human Infection for Vaccination Against Streptococcus Pyogenes (NCT03361163) | Andrew Steer | 2018-07-10 |
| Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients (NCT03438214) | University of Sao Paulo | 2018-04-28 |
| A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting (NCT03159403) | Melinta Therapeutics, Inc. | 2017-04-12 |
| A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013) (NCT02750761) | Merck Sharp & Dohme LLC | 2016-05-02 |
| Telavancin Pediatric PK Study (Ages >12 Months to 17 Years) (NCT02013141) | Cumberland Pharmaceuticals | 2014-12-01 |
| Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients (NCT03560440) | Universitaire Ziekenhuizen KU Leuven | 2014-06-01 |
| Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings (NCT01412801) | Novartis Vaccines | 2011-09-01 |
| Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Finding Study (NCT01212432) | University of Zurich | 2009-12-01 |
| Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and Inflammation (NCT00835783) | Odense University Hospital | 2008-11-01 |
| What is the Prevalence of Methicillin-Resistant Staphylococcus Aureus in Skin and Soft Tissue Infections Presenting to the Emergency Departments of a Canadian Academic Health Care Center? (NCT00736554) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2008-07-01 |
| A Study of Ceftobiprole in Patients With Fever and Neutropenia. (NCT00529282) | Basilea Pharmaceutica | 2007-10-01 |
| Early-Onset Sepsis Surveillance Study (NCT00874367) | NICHD Neonatal Research Network | 2006-02-01 |
| Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections (NCT00501150) | Imperial College London | 2005-09-01 |
| Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections (NCT00108433) | Pfizer | 2005-09-01 |
| Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics (NCT00136292) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2005-08-24 |
| Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit (NCT00167960) | Wyeth is now a wholly owned subsidiary of Pfizer | 2005-01-01 |
| Post Marketing Surveillance Study on Linezolid (NCT01564758) | Pfizer | 2004-02-01 |
| Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA) (NCT00079976) | Wyeth is now a wholly owned subsidiary of Pfizer | 2003-10-01 |
| Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia (NCT00062647) | Cumberland Pharmaceuticals | 2003-08-01 |
| Time To Efficacy and Onset Of Action Of Linezolid (NCT00147511) | Pfizer | 2003-06-01 |
| Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria (NCT00055198) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2002-12-19 |
| Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects (NCT00081744) | Wyeth is now a wholly owned subsidiary of Pfizer | 2002-11-01 |
| Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria (NCT00037050) | Pfizer | 2002-04-01 |
| New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia) (NCT00035269) | Pfizer | 2001-12-01 |
| Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients (NCT00240747) | Pfizer | 2000-06-01 |
| Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis (NCT00406198) | Hopital Lariboisière | 1997-03-01 |